Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Abdi, Jahangir ^a   Mutis, Tuna ^b   Garssen, Johan ^a   Redegeld, Frank ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; WESTERN BLOTTING;

BONE MARROW; CELL LINE, TUMOR; HUMANS; MULTIPLE MYELOMA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSCRIPTOME;

EID: 84876000935     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060671     Document Type: Article

References (25)

1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC, (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
2. Pratt G, Goodyear O, Moss P, (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138: 563-579.
3. Paradisi F, Corti G, Cinelli R (2001) Infections in multiple myeloma. Infect Dis Clin North Am 15: 373-384, vii-viii.
4. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, et al. (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107: 301-304.
5. Brown LM, Gridley G, Check D, Landgren O, (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111: 3388-3394.
6. Chen R, Alvero AB, Silasi DA, Mor G, (2007) Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 57: 93-107.
7. Rakoff-Nahoum S, Medzhitov R, (2009) Toll-like receptors and cancer. Nat Rev Cancer 9: 57-63.
8. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G, (2008) Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene 27: 225-233.
9. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, et al. (2007) Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 7: 1271-1285.
10. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G, (2008) Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112: 2205-2213.
11. Abdi J, Engels F, Garssen J, Redegeld F, (2011) The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. Crit Rev Oncol Hematol 80: 225-240.
12. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C, (2006) Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20: 1130-1137.
13. Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G, (2009) TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol 182: 4471-4478.
14. Bohnhorst J, Rasmussen T, Moen SH, Flottum M, Knudsen L, et al. (2006) Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20: 1138-1144.
15. Xu Y, Zhao Y, Huang H, Chen G, Wu X, et al. (2010) Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol 150: 543-553.
16. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC, (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16: 1362-1371.
17. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, et al. (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96: 284-290.
18. Wang S, Hong S, Yang J, Qian J, Zhang X, et al. (2006) Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108: 4071-4077.
19. Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, et al. (2009) Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 128: 573-579.
20. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A, (2003) The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102: 956-963.
21. Arvaniti E, Ntoufa S, Papakonstantinou N, Touloumenidou T, Laoutaris N, et al. (2011) Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 96: 1644-1652.
22. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, et al. (2007) Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296-304.
23. Rozkova D, Novotna L, Pytlik R, Hochova I, Kozak T, et al. (2010) Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer 126: 1132-1143.
24. Guo Y, Xiao P, Lei S, Deng F, Xiao GG, et al. (2008) How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai) 40: 426-436.
25. Jeannin P, Jaillon S, Delneste Y, (2008) Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 20: 530-537.